Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB.

J Clin Oncol. 2002 Oct 1;20(19):3999-4005.

PMID:
12351597
2.

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA.

J Clin Oncol. 2011 Sep 1;29(25):3381-8. doi: 10.1200/JCO.2010.34.3426. Epub 2011 Jul 25.

3.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.

4.

Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.

Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO, Loconte NK, Greenberg CC, Smith MA.

Ann Surg Oncol. 2014 Jun;21(6):1781-91. doi: 10.1245/s10434-014-3631-8. Epub 2014 Mar 19.

6.

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.

Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD.

J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x. Epub 2009 Jun 25.

PMID:
19563521
7.

Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.

Hanna NN, Onukwugha E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD.

Colorectal Dis. 2012 Jan;14(1):48-55. doi: 10.1111/j.1463-1318.2011.02545.x.

PMID:
21689262
8.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Clin Oncol. 2012 Jul 20;30(21):2624-34. doi: 10.1200/JCO.2011.41.1140. Epub 2012 Jun 4.

9.

Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

Schrag D, Cramer LD, Bach PB, Begg CB.

J Natl Cancer Inst. 2001 Jun 6;93(11):850-7.

PMID:
11390534
10.

The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer.

Gross CP, McAvay GJ, Guo Z, Tinetti ME.

Cancer. 2007 Jun 15;109(12):2410-9.

11.

Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.

Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL.

J Clin Oncol. 2006 May 20;24(15):2368-75. Epub 2006 Apr 17.

PMID:
16618946
12.

Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.

Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI.

Cancer. 2006 Dec 1;107(11):2581-8.

13.

Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer.

Hanna N, Bikov KA, McNally D, Onwudiwe NC, Dalal M, Mullins CD.

Oncologist. 2012;17(9):1191-7. Epub 2012 Jul 5.

14.

Completion of therapy by Medicare patients with stage III colon cancer.

Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W.

J Natl Cancer Inst. 2006 May 3;98(9):610-9.

15.

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422. Epub 2012 Jan 31.

16.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007. Epub 2012 Nov 6.

PMID:
23137529
17.

Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused.

Becerra AZ, Probst CP, Tejani MA, Aquina CT, González MG, Hensley BJ, Noyes K, Monson JR, Fleming FJ.

Surgery. 2015 Sep;158(3):692-9. doi: 10.1016/j.surg.2015.03.057. Epub 2015 May 29.

PMID:
26032822
18.

Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer.

Hsieh MC, Chiu YW, Velasco C, Wu XC, O'Flarity MB, Chen VW.

J Registry Manag. 2013 Winter;40(4):180-7.

PMID:
24625772
19.

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.

Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI.

Ann Intern Med. 2002 Mar 5;136(5):349-57.

PMID:
11874307
20.

Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer.

Young JI, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC, Tsikitis VL.

Dis Colon Rectum. 2016 Apr;59(4):306-15. doi: 10.1097/DCR.0000000000000562.

PMID:
26953989

Supplemental Content

Support Center